Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 5/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HBB | P68871 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL18402620 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL9999636 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10456415-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170035794-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9480698-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9358248-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160130296-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2944646-A1 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | Astex Pharmaceuticals, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-1943264-B1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | ASTEX PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| CN-103945902-A | Decitabine derivative formulations | ASTEX PHARMACEUTICALS INC | 2014-07-23 | — | — | CN | disclosed |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8461123-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | ASTEX PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. | 2010-08-26 | — | — | US | disclosed |
| US-7700567-B2 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | SUPERGEN, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1943264-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SuperGen, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007041071-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215092-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20130236536-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-10456415-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20160130296-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-10933079-B2 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20170035794-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | DCTD, DNMT3B, NT5C3B | DNMT1 7/4885ADRB1 3692/4885LMNA 3943/4885 |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | DCTD, DNMT3B, NT5C3B | DNMT1 8/4885ADRB1 3994/4885LMNA 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.